Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Renovacor has raised $30.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2021.
Renovacor's investors include RTW Investments, BioAdvance, New Leaf Venture Partners, Acorn Bioventures, Novartis Venture Fund.
Renovacor is headquartered in Philadelphia, United States.
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Renovacor is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Renovacor — Funding & Investors." VCBacked, September 3, 2021, https://www.vcbacked.co/company/renovacor. Accessed September 30, 2026.
VCBacked. (2021). Renovacor — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/renovacor
{{cite web |title=Renovacor — Funding & Investors |url=https://www.vcbacked.co/company/renovacor |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated